Ireland - English - HPRA (Health Products Regulatory Authority)

synthon bv - eplerenone - film coated tablet - 25 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

synthon bv - eplerenone - film coated tablet - 50 milligram

United States - English - NLM (National Library of Medicine)

apotex corp - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s j

United States - English - NLM (National Library of Medicine)

greenstone llc - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone is indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (hfref) after an acute myocardial infarction (mi). eplerenone is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and trea

United States - English - NLM (National Library of Medicine)

american health packaging - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction less than or equal to 40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (hfref) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, ev

United States - English - NLM (National Library of Medicine)

eon labs, inc. - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤40%) (hfref) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, ev

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - eplerenone tablets are indicated to improve survival of stable patients with symptomatic heart failure with reduced ejection fraction (≤ 40%) (hfref) after an acute myocardial infarction (mi). eplerenone tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and mi. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. control of high blood pressure should be part of comprehensive cv risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, e

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 50 mg - serum potassium levels should be measured before initiating eplerenone therapy and eplerenone should not be prescribed if serum potassium is >5.5 meq/l. [see 4 contraindications]. eplerenone is indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone is indicated for the treatment of hypertension. eplerenone may be used alone or in combination with other antihypertensive agents. for all patients eplerenone tablets are contraindicated in all patients with: - serum potassium >5.5 meq/l at initiation, - creatinine clearance ≤30 ml/min, or - concomitant administration of strong cyp3a4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). [see drug interactions , 7.1 cyp3a4 inhibitors, clinical pharmacology , 12.3 pharmacokinetics.]  for patients treated for hypertension eplerenon

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - eplerenone (unii: 6995v82d0b) (eplerenone - unii:6995v82d0b) - eplerenone 25 mg - serum potassium levels should be measured before initiating eplerenone therapy and eplerenone should not be prescribed if serum potassium is >5.5 meq/l. [see 4 contraindications]. eplerenone is indicated to improve survival of stable patients with left ventricular (lv) systolic dysfunction (ejection fraction ≤40%) and clinical evidence of congestive heart failure (chf) after an acute myocardial infarction (mi). eplerenone is indicated for the treatment of hypertension. eplerenone may be used alone or in combination with other antihypertensive agents. for all patients eplerenone tablets are contraindicated in all patients with: - serum potassium >5.5 meq/l at initiation, - creatinine clearance ≤30 ml/min, or - concomitant administration of strong cyp3a4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir). [see drug interactions , 7.1 cyp3a4 inhibitors, clinical pharmacology , 12.3 pharmacokinetics.]  for patients treated for hypertension eplerenon